Digest Network Come funziona
Network
/
Società
In
Non verificato

Incyte

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

114 comunicati stampa

Guarda tutti i comunicati
29/07/2026
Industria
Igiene alimentare
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Fonte
Incyte
Emittente
Business Wire
1.00
0
28/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Fonte
Incyte
Emittente
Business Wire
1.00
0
17/07/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
Fonte
Incyte
Emittente
Business Wire
1.00
0
13/07/2026
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Fonte
Incyte
Emittente
Business Wire
1.00
0
08/07/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Incyte to Report Second Quarter Financial Results
Fonte
Incyte
Emittente
Business Wire
1.00
0
06/07/2026
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Fonte
Incyte
Emittente
Business Wire
1.00
0
26/06/2026
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Fonte
Incyte
Emittente
Business Wire
1.00
0
13/06/2026
Eventi
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Fonte
Incyte
Emittente
Business Wire
1.00
0
13/06/2026
Eventi
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Fonte
Incyte
Emittente
Business Wire
1.00
0
08/06/2026
Web e Social Network
Mercato azionario
Telefonia e Varie
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Fonte
Incyte
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0